FIELD: medicine.
SUBSTANCE: invention refers to a combined therapy which provides an anticancer effect of introducing to a person suffering cancer an effective amounts of (SP-4-3)-(cis-amminedichlorine-[2-metylpyridine]platinum (II) (ZD0473) or its prodrug and a non-platinum anticancer agent selected from a group consisting of taxane, camptothecin, gemcytabine, capecitabine, 5-fluorouracil, vinorelbine, topothecane, anthracycline, irinothecane, etoposide, vinblastine, pemetrexede, vindesine, cyclophosphamide, iphosphamide and methotrexate.
EFFECT: synergetic action of ZD0473 and the non-platinum anticancer agent.
26 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| ANTICANCER DRUG CONTAINING CYTIDINE DERIVATIVE AND CARBOPLATIN | 2009 |
|
RU2482855C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
